 |
|
08-23-2008, 07:11 PM
|
#41
|
|
Senior Member
Join Date: Dec 2005
Location: indianapolis, indiana
Posts: 1,544
|
Lani I'm so grateful for all of the information you post for us. It gives me something to print and take with me to the onc when i feel like I should.
__________________
dxd 9-04, lumpectomy,
st 1, gr 3, er,pr-, her2 +,
2 tac,33 rads,6 cmf
1 yr herceptin,
|
|
|
|
08-25-2008, 08:23 AM
|
#42
|
|
Senior Member
Join Date: May 2007
Location: DFW area (TX)
Posts: 431
|
So neither gefitinib or pertuzumab have yet been approved as solo or dual agents? Are either of these in trial right now outside of the "triple agent" scheme? I'm sure I've missed elements of this discussion, and I apologize if so!
TRS
__________________
Terri, spouse of Ruth, Dallas/Ft. Worth area
Ruth dx 05/01/07 (age 50) Filipino
multifocal, several tumors .5 -2.5 cm, large area
Breast MRI showed 2 enlarged nodes, not palpable
100%ER+, 95%PR+, HER2+++
6x pre-surgery TCH chemo finished 9/15/7 Dramatic tumor shrinkage
1 year Herceptin till 6/08
MRM 10/11/07, SNB: 0/4 nodes + Path: tumors reduced to only a few "scattered cells"
now 50% ER+, PR- ???
Rads finished 1/16/08
Added Tamoxifen,
Finished Herceptin 05/08
NOW is the time to appreciate life to the fullest.
|
|
|
|
|
08-25-2008, 09:00 AM
|
#43
|
|
Senior Member
Join Date: Mar 2006
Posts: 4,778
|
gefinitib (tarceva) was approved in Nov 2004 vs lung cancer, in Nov 2005 vspancreatic
cancer when used with gemcitabine. It is a pill.
Pertuzumab has not yet been FDA approved for any use and is not available outside trials, as far as I know.
Genentech website should have more information.
Hope this helps
|
|
|
|
|
08-25-2008, 03:20 PM
|
#44
|
|
Senior Member
Join Date: Nov 2004
Posts: 190
|
I am a drug rep for Roche (we make xeloda). We just announced that we will be buying Genentech. I would really like to see if we can contact someone at Genentech and get them started on the triple threat combo as a study. I am going to start by writing the study nurse who is listed on the trial site. I will see if she can help me get some answers. If any study is done with Dr. Osborne, it will only be located at Baylor. If anybody else has some suggestions, please chime in
Kim
__________________
8/98 dx right breast
5/2003 tram flap right breast
8/2004 dx new primary left breast with inflammatory bc
er/pr-, her2neu+++
8/19 taxotere and herceptin
1/15/2005 Navelbine/Herceptin
4/2005 radiation and Herceptin
5/15/2005 Herceptin alone
2/12/2008 skin biopsy positive
2/14/2008 met to sternum, possibly right breast
2/27/08 Start omitarg, herceptin, taxotere trial
3/17/08 Kicked off trial because I started too close to my last herceptin
3/19 start tykerb xeloda
Right breast confirmed met
5/15/08 skin mets gone, no hypermetabolic activity in breast, sternum healing
8/24/08 scans still look good. sternum still active with scarring. No evidence of progression
10/08 Progression in sternum
12/08 Start TDM1 trial
1/09 Scans show stable
12/09 1 year on TDM1 still stable
10/10 progression in chest and liver
11/10 false positive of liver mets; tykerb and herceptin
4/11 Tykerb/Herceptin/Xgeva
4/11 Rads to Sternum
5/12/12 NED Herceptin/Zometa
3/16/19 still NED Herceptin/Zometa very 6months
|
|
|
|
|
08-25-2008, 04:07 PM
|
#45
|
|
Senior Member
Join Date: Sep 2005
Posts: 589
|
Go get em Kim!
|
|
|
|
|
08-26-2008, 07:40 AM
|
#46
|
|
Senior Member
Join Date: May 2007
Location: DFW area (TX)
Posts: 431
|
Fantastic. I hope that Kim can go armed with knowledge and wisdom.
__________________
Terri, spouse of Ruth, Dallas/Ft. Worth area
Ruth dx 05/01/07 (age 50) Filipino
multifocal, several tumors .5 -2.5 cm, large area
Breast MRI showed 2 enlarged nodes, not palpable
100%ER+, 95%PR+, HER2+++
6x pre-surgery TCH chemo finished 9/15/7 Dramatic tumor shrinkage
1 year Herceptin till 6/08
MRM 10/11/07, SNB: 0/4 nodes + Path: tumors reduced to only a few "scattered cells"
now 50% ER+, PR- ???
Rads finished 1/16/08
Added Tamoxifen,
Finished Herceptin 05/08
NOW is the time to appreciate life to the fullest.
|
|
|
|
|
08-27-2008, 06:06 AM
|
#47
|
|
Senior Member
Join Date: Nov 2004
Posts: 190
|
Well I tried writing Genentech but I got the run around. They asked me what my position was with Roche. Then she told me that I need to contact some one at Roche for more info. I'm afraid I not high enough in the food chain for them to just outright give up imformation.
We have a national meeting at the end of September. All the big shots will be there. I'm going to have to make a bold move and go up to one of these guys
Kim
__________________
8/98 dx right breast
5/2003 tram flap right breast
8/2004 dx new primary left breast with inflammatory bc
er/pr-, her2neu+++
8/19 taxotere and herceptin
1/15/2005 Navelbine/Herceptin
4/2005 radiation and Herceptin
5/15/2005 Herceptin alone
2/12/2008 skin biopsy positive
2/14/2008 met to sternum, possibly right breast
2/27/08 Start omitarg, herceptin, taxotere trial
3/17/08 Kicked off trial because I started too close to my last herceptin
3/19 start tykerb xeloda
Right breast confirmed met
5/15/08 skin mets gone, no hypermetabolic activity in breast, sternum healing
8/24/08 scans still look good. sternum still active with scarring. No evidence of progression
10/08 Progression in sternum
12/08 Start TDM1 trial
1/09 Scans show stable
12/09 1 year on TDM1 still stable
10/10 progression in chest and liver
11/10 false positive of liver mets; tykerb and herceptin
4/11 Tykerb/Herceptin/Xgeva
4/11 Rads to Sternum
5/12/12 NED Herceptin/Zometa
3/16/19 still NED Herceptin/Zometa very 6months
|
|
|
|
|
08-27-2008, 12:39 PM
|
#48
|
|
Senior Member
Join Date: Sep 2005
Location: Alaska
Posts: 2,018
|
Applicability of treatment
In reading the previous posts there were some that quite naturally express disappointment that a clinical trial might be limited to the newly diagnosed, and that brought up a consideration about so many of the results of non-human lab research:
STUDY INFO:
A clinical study using drug combinations in newly diagnosed patients with HER-2 positive breast cancer will start soon under the direction of physicians at BCM's BreastCenter, said Osborne.
"We are very excited to see if our laboratory results can be translated to patients with the more aggressive types of breast cancer," he said.
Methods: Mice carrying xenograft tumors of HER2-overexpressing MCF7/HER2-18 (HER2-transfected) or BT474 (HER2-amplified) cells were treated with estrogen supplementation or estrogen withdrawal, alone or combined with tamoxifen. One to three HER inhibitors (pertuzumab, trastuzumab, or gefitinib) could also be added (n ?8 mice per group).
LANI's comment:
"One of the big differences between that abstract and this article is that in the study cited in the ASCO abstract they used not only MCF7 cells transfected with her2 (an artificial construct which may not have any similarity to any naturally occuring tumor) but also BT474
a tumor which naturally occured in the poor person whose cell line was propagated and perpetuated which is her amplified (eg FISH+) and ER+. This human breast cancer cell line was implanted into the rodent,so...
This is as close as it gets to simulating her2+ER+ breast cancer as it occurs in humans."
ALASKAANGEL: This would be wonderful for all newly diagnosed patients. But unless the mice have been treated previously or simultaneously with the standard chemotherapy regimens that patients get, how can we know how for sure how this will work for many of us?
|
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT -7. The time now is 01:53 PM.
|
Linear Mode
